Dose-dependent FODMAP Reintroduction in IBS

Not Applicable

Recruiting

• Conditions: Irritable Bowel Syndrome
• Interventions: Other: FODMAP powder reintroduction

• Registration Number: NCT05808023
• Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Brief Summary

The aim of this study is to evaluate whether symptom recurrence, after successful FODMAP elimination, is dose-dependent in patients with IBS. The effect of a blinded reintroduction of FODMAP powders fructans and mannitol will be investigated in a crossover dose-escalation scheme for the identification of the eliciting dose in individual patients. The reintroduction of FODMAPs is performed after a successful elimination by the LFD.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-03-15
• Study Start: 2023-04-01
• Study First Submitted QC: 2023-04-07
• Study First Posted: 2023-04-11
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-28
• Last Update Posted: 2024-07-01
• Primary Completion: 2024-10
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
2. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
3. Patients with irritable bowel syndrome according to Rome IV diagnostic criteria
4. Patients ages between 18 and 70 years old

Exclusion Criteria

1. Participant has a history of any major psychiatric disorders (including those with a major psychosomatic element to their gastrointestinal disease), depression, alcohol or substance abuse in the last 2 years

2. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol

3. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial

4. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive

5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device

6. Patients presenting with predominant symptoms of functional dyspepsia (FD) and of gastro-oesophageal reflux disease (GERD)

7. Patients following a diet interfering with the study diet in opinion of the investigator

8. Patients who already followed the low FODMAP diet under guidance of a trained dietitian without success.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Fructans	FODMAP powder reintroduction	Fructans belong to the group of oligosaccharides, specifically the fructose-oligosaccharides (FOS), within the FODMAPs.
Mannitol	FODMAP powder reintroduction	Mannitol belongs to the group of polyols within the FODMAPs.

Primary Outcome Measures

Name	Time	Method
Dose dependency	18 months	The study aims to determine the daily dose level of mannitol or fructans that induces symptom recurrence in IBS.

Trial Locations

Locations (1)

AZ Sint Lucas; 🇧🇪 Brugge, Belgium